首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1532527

尿病治疗市场- 依治疗类型（药物[抗生素、α-受体阻断剂]、引流装置[导管、输尿管支架]、手术程序）、年龄组（20岁以下、21-40岁、41-60岁、61-80岁）、结束-user - 全球预测（2024 - 2032）

Uropathy Treatment Market - By Treatment Type (Medication [Antibiotics, Alpha-blockers], Drainage Devices [Catheter, Ureteral Stents], Surgical Procedure), Age Group (Below 20, 21 - 40, 41 - 60, 61 - 80), End-user - Global Forecast (2024 - 2032)

出版日期: 2024年05月22日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在医疗支出增加和获得先进治疗的机会增加的推动下，2024 年至 2032 年全球尿路病治疗市场的复合年增长率将达到 4.1%。根据世界卫生组织报告，2022年全球医疗保健支出将达到约8.6兆美元，预计年增率为5.4%。政府和私人实体资金的增加促进了医疗研发，从而带来更好的诊断工具和治疗选择。改善的医疗基础设施能够更早发现并有效管理泌尿系统疾病，满足日益增长的泌尿系统疾病照护需求。

泌尿系统疾病（例如泌尿道感染、肾结石和膀胱控制问题）的盛行率不断上升，特别是在老年人口中，显着增加了对有效治疗的需求。诊断工具和治疗方案的技术进步，包括微创手术技术、创新药物疗法和先进的医疗设备，正在改善患者的治疗效果并扩大治疗的可能性。

尿路病治疗市场根据治疗类型、年龄层、最终用户和地区进行分类。

由于人们对泌尿系统疾病的认识提高和早期诊断，到 2032 年，药物领域的复合年增长率将达到显着水准。患者和医疗保健提供者正在寻求有效的药物选择来管理这些病症。重点是个人化医疗和更好的治疗结果。药物开发的创新和治疗方法的增加，以及公众认知度的提高，将推动对泌尿道病药物的需求。

由于压力水平和生活方式因素增加，导致泌尿系统疾病盛行率上升，到 2032 年，21-40 岁年龄层将获得强大的泌尿系统疾病治疗市场份额。此外，更高的健康意识和积极主动的医疗保健方法会导致更频繁的诊断和治疗。数位健康工具和远距医疗在年轻人中的广泛使用也使泌尿科咨询和治疗变得更加容易。此外，生育年龄和相关泌尿系统健康问题（例如生育问题和性传染感染）在这群人中普遍存在，进一步推动了对专门泌尿道疾病治疗的需求。

在医疗保健普及和泌尿系统疾病盛行率上升的支持下，北美泌尿道治疗市场在预测期内将录得显着的复合年增长率。健康保险的覆盖和先进的医疗设施导致更多的人寻求诊断和治疗。对健康优化的高认识水准和重视加强了预防性护理和早期干预，从而增加了对综合尿路病解决方案的需求。包括可支配收入增加在内的社会经济因素将进一步推动北美的产业发展轨迹。

产业生态系统分析
产业影响力
- 成长动力
  - 泌尿系统疾病盛行率增加
  - 人们越来越偏好微创手术
  - 导管和支架的技术进步
- 产业陷阱与挑战
  - 支架和导管导致感染和不适的风险
监管环境
管道分析
未来市场趋势
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

主要趋势
药物
- 抗生素
- α-阻断剂或α-还原酶抑制剂
- 其他药物
排水装置
- 导管
  - 留置导管
  - 间歇导管
  - 耻骨上导管
- 输尿管支架
手术过程
其他治疗类型

第 6 章：市场估计与预测：按年龄划分，2021 - 2032

主要趋势
20岁以下
21 - 40
41 - 60
61 - 80

第 7 章：市场估计与预测：按最终用户划分，2021 - 2032 年

主要趋势
医院
门诊手术中心
专科诊所
其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Astellas Pharma Inc.
B. Braun Melsungen AG
Becton, Dickinson, and Company
Boston Scientific Corporation
Cook Medical
Glaxo SmithKline Pharmaceuticals Ltd.
Inceler Medikal Co. Ltd.
KARL STORZ
Purdue Pharma
Olympus America
Pfizer Inc.
Sun Pharmaceutical Industries Europe B.V.
Synthon BV
Teleflex Incorporated.
UROMED Kurt Drews KG

简介目录

Product Code: 9581

Global Uropathy Treatment Market will exhibit 4.1% CAGR from 2024 to 2032, thrusted by increasing healthcare expenditure and enhancing access to advanced treatments. According to the WHO reports, global healthcare spending reached approximately 8.6 trillion in 2022, with a projected annual growth rate of 5.4%. The rise in funding from governments and private entities facilitates medical R&D, leading to better diagnostic tools and treatment options. The improved medical infrastructure enables earlier detection and effective management of urological disorders, meeting the rising demand for uropathy care.

The rising prevalence of urological disorders, such as urinary tract infections, kidney stones, and bladder control issues, particularly among the aging population, is significantly increasing the demand for effective treatments. Technological advancements in diagnostic tools and treatment options, including minimally invasive surgical techniques, innovative drug therapies, and advanced medical devices, are improving patient outcomes and expanding treatment possibilities.

The uropathy treatment market is categorized based on treatment type, age group, end-user, and region.

The medications segment will register a noteworthy CAGR through 2032, owing to increased awareness and early diagnosis of urological disorders. Patients and healthcare providers are seeking effective pharmacological options for managing these conditions. There is focus on personalized medicine and better treatment outcomes. Innovations in drug development and greater availability of treatments, with improved cognizance amongst public, will propel the demand for uropathy medications.

The 21-40 years age segment will attain a strong uropathy treatment market share by 2032, due to increased stress levels and lifestyle factors, leading to rising prevalence of urological conditions. Additionally, greater health awareness and proactive healthcare approaches lead to more frequent diagnoses and treatments. The widespread use of digital health tools and telemedicine among younger adults is also facilitating easier access to urological consultations and treatments. Additionally, the reproductive age and associated urological health concerns, such as fertility issues and sexually transmitted infections, are prevalent in this group, further driving the need for specialized uropathy treatments.

North America uropathy treatment market will record a remarkable CAGR during the forecast period, backed by the increasing healthcare access and rising prevalence of urological conditions. The presence of health insurance coverage and advanced medical facilities lead to more individuals seeking diagnosis and treatment. The high awareness levels and emphasis on health optimization augment preventative care and early intervention, boosting the demand for comprehensive uropathy solutions. Socioeconomic factors, including higher disposable incomes, will further catalyze the industry trajectory in North America.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of urological disorders
  - 3.2.1.2 Growing preference for minimally invasive procedures
  - 3.2.1.3 Technological advancements in catheters and stents
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Risk of infection and discomfort due to stents and catheters
3.3 Regulatory landscape
3.4 Pipeline analysis
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Medication
- 5.2.1 Antibiotics
- 5.2.2 Alpha-blockers or alpha-reductase inhibitors
- 5.2.3 Other medication
5.3 Drainage devices
- 5.3.1 Catheters
  - 5.3.1.1 Indwelling catheters
  - 5.3.1.2 Intermittent catheter
  - 5.3.1.3 Suprapubic catheter
- 5.3.2 Ureteral stents
5.4 Surgical procedure
5.5 Other treatment types

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Below 20
6.3 21 - 40
6.4 41 - 60
6.5 61 - 80

Chapter 7 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Ambulatory surgical centers
7.4 Specialty clinics
7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 The Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa